Ascentage Pharma Forms Clinical Collaboration with MD Anderson Center

Shanghai's Ascentage Pharma announced a five-year strategic collaboration with The University of Texas MD Anderson Cancer Center for clinical development of five potential cancer therapies. The five candidates, which are apoptosis-targeted and tyrosine kinase inhibitors, were discovered by Ascentage's Protein-Protein Interaction platform. They will be studied as single-agent therapies and in combination with approved or investigational drugs as treatments for various hematologic malignancies. More details....

Share this with colleagues:

Original Article: Ascentage Pharma Forms Clinical Collaboration with MD Anderson Center

More From BioPortfolio on "Ascentage Pharma Forms Clinical Collaboration with MD Anderson Center"